Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jun 26, 2024; 16(6): 670-689
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.670
Mesenchymal stem cells-extracellular vesicles alleviate pulmonary fibrosis by regulating immunomodulators
Ying Gao, Mei-Fang Liu, Yang Li, Xi Liu, Yu-Jie Cao, Qian-Fa Long, Jun Yu, Jian-Ying Li
Ying Gao, Department of Respiratory and Critical Care Medicine, Shaanxi Provincial Rehabilitation Hospital, Xi’an 710000, Shaanxi Province, China
Mei-Fang Liu, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Ningxia Medical University (The First People’s Hospital of Yinchuan), Yinchuan 750001, Ningxia Hui Autonomous Region, China
Yang Li, School of Clinical Medicine, Xi’an Medical University, Xi’an 710021, Shaanxi Province, China
Xi Liu, Yu-Jie Cao, Jian-Ying Li, Department of Respiratory and Critical Care Medicine, Xi’an Central Hospital, Xi’an 710000, Shaanxi Province, China
Qian-Fa Long, Department of Neurosurgery, Xi’an Central Hospital, Xi’an 710000, Shaanxi Province, China
Jun Yu, Department of Emergency, Xi’an Central Hospital, Xi’an 710000, Shaanxi Province, China
Author contributions: Gao Y and Liu MF carried out the experiments, participated in the data collection, and drafted the manuscript; Li Y, Liu X, and Cao YJ performed the statistical analysis and participated in the study design; Long QF, Yu J, and Li JY helped draft the manuscript; and all authors read and approved the final manuscript.
Supported by Xi’an Science and Technology Plan Project, No. 20200001YX001(1); and Xi’an Talent Plan - Elite (Innovative Talents) Project, No. XAYC210062.
Institutional review board statement: This study was approved by the Ethics Committee guidelines of Xi’an Central Hospital, No. LW-2023-032.
Institutional animal care and use committee statement: All animal procedures were performed in accordance with the guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were approved by the hospital’s ethical committee for animals, No. IACUC-20210211.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Ying Li, MD, Doctor, Department of Respiratory and Critical Care Medicine, Xi’an Central Hospital, No. 163 West Fifth Road, Xi’an 710000, Shaanxi Province, China. l13572168322@163.com
Received: January 6, 2024
Revised: March 22, 2024
Accepted: May 11, 2024
Published online: June 26, 2024
Processing time: 171 Days and 8 Hours
Core Tip

Core Tip: This study unveils the innovative potential of mesenchymal stem cells-extracellular vesicles (MSC-EVs) in mitigating pulmonary fibrosis (PF). MSC-EVs effectively countered transforming growth factor-β1-induced fibrosis in A549 cells, showcasing a significant reduction in collagen I and α-smooth muscle actin. The treatment exhibited a dual impact, alleviating oxidative stress and inflammatory responses in vitro. In PF mouse lungs, MSC-EVs demonstrated remarkable downregulation of fibrotic markers and modulation of oxidative stress and inflammation.